Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat severe atopic dermatitis in children aged 6 to 11 years ...

Sanofi's 'Dupixent' (ingredient: dupilumab), which utilizes Alteogen's subcutaneous (SC) injection platform technology, has ...

Dupilumab (Dupixent) relieves signs and symptoms of eosinophilic esophagitis (EoE) for up to 52 weeks, researchers say. Few side effects, other than injection pain, emerged in the year-long phase 3 ...

Approval is based on Phase 3 trial results showing Dupixent significantly improved disease extent and severity, skin clearance, and itch intensity, as well as sleep and health-related quality of life ...

The expanded indication makes dupilumab the only approved treatment for eosinophilic esophagitis (EoE) in this age group. Dupilumab (Dupixent) is the first FDA-approved treatment for children aged 1 ...

Individuals with severe type 2 asthma and chronic rhinosinusitis with nasal polyps may benefit from the biologic treatment, dupilumab. A study on the efficacy of the biologic drug, dupilumab, found ...

Mild-to-moderate Atopic Dermatitis (AD) may be adequately treated with a combination of trigger avoidance, moisturizers, topical corticosteroids, calcineurin inhibitors and/or crisaborole. However, ...

An experimental oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, showed greater itch reduction after 2 weeks of treatment than dupilumab in patients with moderate to severe atopic dermatitis (AD), ...

UNITED LABORATORIES (03933.HK) announced that the atopic dermatitis indication for the dupilumab biosimilar injection ...

Please provide your email address to receive an email when new articles are posted on . Researchers gave a double-blind placebo-controlled food challenge with at least 444 mg peanut protein to a ...

A revolutionary injection for chronic obstructive pulmonary disorder (COPD) is being rolled out on the NHS. The jab tackles the inflammation driving symptoms and could benefit up to 30,000 people with ...